374
J. Qu and J. Zhang
99. Mercey R, Lantier I, Maurel MC, Grosclaude J, Lantier F, Marc D (2006) Fast, reversible
interaction of prion protein with RNA aptamers containing specific sequence patterns. Adv
Virol 151(11):2197–2214. https://doi.org/10.1007/s00705-006-0790-3
100. Mashima T, Matsugami A, Nishikawa F, Nishikawa S, Katahira M (2009) Unique quadruplex
structure and interaction of an RNA aptamer against bovine prion protein. Nucl Acids Res
37(18):6249–6258. https://doi.org/10.1093/nar/gkp647
101. Spinney L (2010) Uncovering the true prevalence of Huntington’s disease. Lancet Neurol
9(8):760–761. https://doi.org/10.1016/S1474-4422(10)70160-5
102. Munoz-Sanjuan I, Bates GP (2011) The importance of integrating basic and clinical research
toward the development of new therapies for Huntington disease. J Clin Investig 121(2):476–
483. https://doi.org/10.1172/JCI45364
103. Chaudhary RK, Patel KA, Patel MK, Joshi RH, Roy I (2015) Inhibition of Aggregation
of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington’s Disease. Molecular therapy: the journal of the American Society of Gene Therapy
23(12):1912–1926. https://doi.org/10.1038/mt.2015.157
104. Shin B, Jung R, Oh H, Owens GE, Lee H, Kwak S, Lee R, Cotman SL, Lee JM, MacDonald
ME, Song JJ, Vijayvargia R, Seong IS (2018) Novel DNA aptamers that bind to mutant
huntingtin and modify its activity. Mol Ther Nucl Acids 11:416–428. https://doi.org/10.1016/
j.omtn.2018.03.008
105. Skogen M, Roth J, Yerkes S, Parekh-Olmedo H, Kmiec E (2006) Short G-rich oligonucleotides
as a potential therapeutic for Huntington’s Disease. BMC Neurosci 7:65. https://doi.org/10.
1186/1471-2202-7-65
106. Patel KA, Chaudhary RK, Roy I (2018) RNA aptamers rescue mitochondrial dysfunction in a
yeast model of huntington’s disease. Mol Ther Nucl Acids 12:45–56. https://doi.org/10.1016/
j.omtn.2018.04.010
107. Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov
9(7):537–550. https://doi.org/10.1038/nrd3141
108. Hu M, Zhang K (2013) The application of aptamers in cancer research: an up-to-date review.
Future Oncol 9(3):369–376. https://doi.org/10.2217/fon.12.201
109. Yang Y, Ren X, Schluesener HJ, Zhang Z (2011) Aptamers: selection, modification and
application to nervous system diseases. Curr Med Chem 18(27):4159–4168. https://doi.org/
10.2174/092986711797189646
J. Qu and J. Zhang
99. Mercey R, Lantier I, Maurel MC, Grosclaude J, Lantier F, Marc D (2006) Fast, reversible
interaction of prion protein with RNA aptamers containing specific sequence patterns. Adv
Virol 151(11):2197–2214. https://doi.org/10.1007/s00705-006-0790-3
100. Mashima T, Matsugami A, Nishikawa F, Nishikawa S, Katahira M (2009) Unique quadruplex
structure and interaction of an RNA aptamer against bovine prion protein. Nucl Acids Res
37(18):6249–6258. https://doi.org/10.1093/nar/gkp647
101. Spinney L (2010) Uncovering the true prevalence of Huntington’s disease. Lancet Neurol
9(8):760–761. https://doi.org/10.1016/S1474-4422(10)70160-5
102. Munoz-Sanjuan I, Bates GP (2011) The importance of integrating basic and clinical research
toward the development of new therapies for Huntington disease. J Clin Investig 121(2):476–
483. https://doi.org/10.1172/JCI45364
103. Chaudhary RK, Patel KA, Patel MK, Joshi RH, Roy I (2015) Inhibition of Aggregation
of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington’s Disease. Molecular therapy: the journal of the American Society of Gene Therapy
23(12):1912–1926. https://doi.org/10.1038/mt.2015.157
104. Shin B, Jung R, Oh H, Owens GE, Lee H, Kwak S, Lee R, Cotman SL, Lee JM, MacDonald
ME, Song JJ, Vijayvargia R, Seong IS (2018) Novel DNA aptamers that bind to mutant
huntingtin and modify its activity. Mol Ther Nucl Acids 11:416–428. https://doi.org/10.1016/
j.omtn.2018.03.008
105. Skogen M, Roth J, Yerkes S, Parekh-Olmedo H, Kmiec E (2006) Short G-rich oligonucleotides
as a potential therapeutic for Huntington’s Disease. BMC Neurosci 7:65. https://doi.org/10.
1186/1471-2202-7-65
106. Patel KA, Chaudhary RK, Roy I (2018) RNA aptamers rescue mitochondrial dysfunction in a
yeast model of huntington’s disease. Mol Ther Nucl Acids 12:45–56. https://doi.org/10.1016/
j.omtn.2018.04.010
107. Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov
9(7):537–550. https://doi.org/10.1038/nrd3141
108. Hu M, Zhang K (2013) The application of aptamers in cancer research: an up-to-date review.
Future Oncol 9(3):369–376. https://doi.org/10.2217/fon.12.201
109. Yang Y, Ren X, Schluesener HJ, Zhang Z (2011) Aptamers: selection, modification and
application to nervous system diseases. Curr Med Chem 18(27):4159–4168. https://doi.org/
10.2174/092986711797189646